Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$0.69 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$68.32M
Enterprise Value$74.13
Total Cash (Recent Filing)$40.65M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 06, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding86,267,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt limits leverage and interest-burden risk, giving Rein greater flexibility to fund clinical development. This is a durable financial strength, although continued losses could still erode equity and liquidity over time.
Improved CapitalizationThe rebound in equity indicates that capital raising or restructuring has strengthened the funding base for ongoing development. It provides a larger cushion than in 2025, though future financing may still be required before commercialization.
Reduced Operating BurnThe substantial reduction in operating losses suggests better cost control or lower development spending relative to 2024. Sustaining this improvement could extend the company’s runway, even though it remains deeply unprofitable and pre-revenue.
Bears Say
No Commercial RevenueWith no commercial revenue, Rein lacks an internal funding engine and remains dependent on financing, partnerships, or successful clinical development. This limits financial visibility and makes the business model vulnerable to delays in reaching commercialization.
Severe Ongoing LossesLarge recurring losses reflect the high cost of advancing therapies without product sales and can steadily reduce equity if not offset by funding or revenue. Continued losses also increase the financial consequences of clinical setbacks or development delays.
Funding And Dilution RiskPersistent cash consumption requires external capital to maintain operations, while the larger authorized share pool facilitates future equity financing. This improves funding flexibility but creates a durable risk of shareholder dilution before revenue is established.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.69 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $68.32M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 76 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.07.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 86,267,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 2.414%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (376.19% Upside)
$6.00 (376.19% Upside)
Blogger Sentiment
Bullish
RNTX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $49.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.78%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$6.00
▲(376.19% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
XBiotech
―
Elicio Therapeutics
―
Xilio Therapeutics
―
Ownership Overview
1.76% Insiders
1.37% Mutual Funds
36.34% Other Institutional Investors
56.50% Public Companies and
Individual Investors